There was significant increase in the cancer detection rate in the patient subgroup with a PSA level of 4–10 ng/ml, PSAD of 0.12–0.20 ng/ml2, prostate volume >50 ml, negative TRUS findings and negative DRE findings, and the P-values were 0.0256, 0.0133, 0.0099, 0.0027 and 0.0037, respectively. The gene discussed is KLK3; the disease is cancer.